Toll‐like receptor 5 and 8 in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Toll‐like receptor 5 and 8 in hepatocellular carcinoma

Published:2021-06 Issue:8 Volume:129 Page:470-479
ISSN:0903-4641
Container-title:APMIS
language:en
Short-container-title:APMIS

Author:

Kairaluoma Valtteri¹,Kemi Niko¹,Huhta Heikki¹,Pohjanen Vesa‐Matti²,Helminen Olli¹

Affiliation:

1. Surgery Research Unit Medical Research Center Oulu, Cancer and Translational Medicine Research Unit University of Oulu and Oulu University Hospital Oulu Finland

2. Cancer and Translational Medicine Research Unit Medical Research Center University of Oulu and Oulu University Hospital Oulu Finland

Funder

Suomen Lääketieteen Säätiö

Instrumentariumin Tiedesäätiö

Publisher

Wiley

Subject

Microbiology (medical),General Medicine,Immunology and Allergy,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apm.13142

Reference47 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Resectability of hepatocellular carcinoma: evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature;Sotiropoulos GC;Hepatogastroenterology

3. Toll-Like Receptors

4. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

5. Toll-Like Receptor Signaling Pathways

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA m5C methylation: a potential modulator of innate immune pathways in hepatocellular carcinoma;Frontiers in Immunology;2024-05-13

2. TLR AND CANCER: THE ENIGMATIC CROSS TALK;Thirty Years since the Discovery of Toll-Like Receptors;2024-03-20

3. Prognostic Value of an Immune Long Non-Coding RNA Signature in Liver Hepatocellular Carcinoma;Journal of Microbiology and Biotechnology;2024-01-30

4. Multiple Factors Determine the Oncolytic or Carcinogenic Effects of TLRs Activation in Cancer;Journal of Immunology Research;2024-01-13

5. Gut microbiota in MAFLD: therapeutic and diagnostic implications;Therapeutic Advances in Endocrinology and Metabolism;2024-01